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Blockade of CD354 (TREM-1) Ameliorates Anti-GBM-Induced
Nephritis
Yong Du,1,2 Tianfu Wu,1,2 Xin J. Zhou,3 Laurie S. Davis,1,4 and Chandra Mohan1,2
Abstract—CD354, Triggering Receptor of Myeloid Cells-1 (TREM-1), is a potent amplifier of myeloid
immune responses. Our goal was to determine the expression and function of TREM-1 in immune-
mediated nephritis. An anti-glomerular basement membrane antibody (anti-GBM)-induced nephritis
model was employed, where mice were sensitized with rabbit IgG followed by anti-GBM serum to
induce disease. Anti-GBM-treated 129x1/svJ mice developed severe nephritis whereas C57BL/6 (B6)
mice were resistant to disease. Anti-GBM disease resulted in elevated renal TREM-1 messenger RNA
(mRNA) and protein levels and increased urine TREM-1 levels in 129x1/svJ. TREM-1 blockade with an
inhibitory peptide, LP17, inhibited proteinuria and renal disease as measured by glomerulonephritis
class, severity of tubulointerstitial disease, crescent formation, and inflammatory cell infiltrates. In sum,
TREM-1 is upregulated in renal inflammation and plays a vital role in driving disease. Thus, TREM-1
blockade emerges as a potential therapeutic avenue for immune-mediated renal diseases such as lupus
nephritis.
KEYWORDS: anti-glomerular basement membrane antibody-induced nephritis; Triggering Receptor Expressed by
Myeloid Cells-1 (TREM-1); immune-mediated nephritis; SLE, systemic lupus erythematosus; immunotherapy.
INTRODUCTION
Renal inflammation leading to organ dysfunction
and end-stage disease is a common feature of auto-
immune diseases such as systemic lupus erythemato-
sus (SLE) [1, 2]. Increased knowledge of pathogenic
mechanisms could greatly enhance prognosis and
treatment of kidney diseases. Murine models suggest
that contributing factors to immune-mediated nephri-
tis include autoantibodies such as anti-glomerular
antibodies [3, 4] and innate immune activation inde-
pendent of autoantibody production [5, 6]. Dendritic
cells maintain renal self-tolerance mediated by T
regulatory cells [7]. However, resident macrophages
and recruited monocytes regulate renal inflammation
which can involve renal cells [8, 9].
Anti-glomerular basement membrane antibody
(anti-GBM)-induced disease or Goodpasture’s syn-
drome is characterized by antibodies with specific-
ities to renal targets, such as collagen type IV in
glomerular basement membranes [10]. Murine models
mimicking human anti-GBM nephritis require immu-
nization with collagen type IV or heterologous anti-
GBM antibodies which initiate an autoimmune
antibody-mediated inflammatory response [10]. The
murine anti-GBM model shares a number of charac-
teristics with spontaneous lupus murine models in
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regard to pathogenic mechanisms contributing to ne-
phritis including shared molecular mediators such as
complement, FcR, toll- l ike receptors (TLR),
costimulatory receptors, adhesion receptors, cyto-
kines, chemokines, and other mediators [11–13].
Thus, the anti-GBM model provides a unique ap-
proach for rapidly screening agents with potential
therapeutic efficacy for other more protracted varie-
ties of immune-mediated nephritis such as lupus
nephritis.
This study was designed to determine whether
the novel inhibitory peptide LP17, targeting the
CD354 receptor, Triggering Receptor Expressed on
Myeloid Cells-1 or TREM-1, could impact anti-
GBM nephritis. TREM-1 was first described as a
costimulatory receptor on myeloid cells [14, 15].
TREM-1 potently amplified the function of TLR
and Nod-like receptors (NLR) which resulted in en-
hanced cytokine production [14, 15]. Early studies
reported a role for TREM-1 in sepsis models and
found that soluble TREM-1 could serve as a bio-
marker for acute inflammation during infection [16,
17]. Protective effects of TREM-1 blockade were
also documented in acute infections [14, 18]. Subse-
quently, a role for TREM-1 in the amplification of
noninfectious inflammatory responses was reported
[14, 17, 19]. Recently, TREM-1 activation by self-
proteins in the absence of TLR/NLRs has been
shown to stimulate monocyte cytokine production
[20]. Antagonizing TREM-1 with antibodies, fusion
proteins, or inhibitory peptides reduces inflammation
in experimental arthritis and colitis models [14, 21,
22]. This report represents a first step toward reveal-
ing the contribution of TREM-1 to inflammatory
kidney diseases. The current study demonstrates that
the LP17 inhibitory peptide targeting TREM-1 pro-
foundly subdues anti-GBM-mediated nephritis.
MATERIALS AND METHODS
Mice and Anti-GBM Nephritis Model
Female 129x1/svJ mice and C57BL/6 (B6) con-
trols (Jackson Laboratories) were maintained in a
pathogen-free colony. Animal experiments were ap-
proved and conducted in accordance with UT South-
western’s Institutional Animal Care and Use Commit-
tee guidelines which comply with all applicable in-
ternational and national guidelines for the care and
use of animals. Anti-GBM serum was purchased
from Lampire Laboratories [23, 24]. Anti-GBM ne-
phritis was induced in 8–12-week-old female mice
[4, 23]. Briefly, mice were pre-sensitized with rabbit
IgG 250 μg/mouse, given intraperitoneally (i.p.) in
complete Freund’s adjuvant (Sigma). Five days later,
the mice received rabbit anti-GBM serum 200 μg
IgG/25 g body weight, administered intravenously
(i.v.) [4, 23]. This dosing regimen was sufficient to
induce proteinuria but not mortality. Experiments are
representative of three independent experiments.
TREM-1 Blockade
Upon nephritis induction, mice were randomly assigned
to receive either an antagonistic TREM-1 peptide, LP17
(LQVTDSGLYRCVIYHPP), a sequence-scrambled control
peptide (TDSRCVIGLYHPPLQVY), or 100 μl phosphate
buffered saline (PBS) alone as vehicle control [18]. The
peptides were chemically synthesized as COOH terminally
amidated peptides (Pepscan Systems). Mice were treated
daily with 200 μg peptide in 50–100 μl PBS through i.p.
injection initiated on day 7 (D7). Weekly serum samples and
24-h urine samples were collected as described [4, 23, 24].
Renal Histopathology
Kidney specimens were prepared as 4-μm sections of
formalin-fixed, dehydrated, and paraffin-embedded tissues
[4, 23, 24]. Slides were stained with hematoxylin and eosin
or periodic acid-Schiff (PAS). Replicate sections were ex-
amined for pathological changes in glomeruli, tubules, or
interstitial areas in a blinded fashion [4, 25]. Glomerulone-
phritis (GN) was graded on a 0–5 scale, while percent
crescent formation and the tubulointerstitial nephritis (TI)
score were graded on 0–4 scales [4, 23, 24]. Macrophages
were stained with Iba1 (Wako Chemicals), and intrarenal
leukocytes and macrophages were enumerated. Standard
immunofluorescence and avidin-biotin complex methods
were used for target detection [4, 25].
Sample Preparation and TREM-1 Enzyme-Linked
Immunosorbent Assay (ELISA)
All serum and urine samples were collected on
the days indicated and centrifuged at 14,000 rpm for
5 min, immediately aliquoted and rapidly frozen.
Clear supernatants were assayed for total protein with
a Coomassie Plus Kit (Pierce). The serum and urine
creatinine levels were measured by capillary electro-
phoresis diode array detector in the UT Southwestern
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Metabolomics core. Proteinuria was detected for sam-
ples collected over a 24-h period as described [25].
Renal eluates were prepared as described [4, 23, 24].
Soluble TREM-1 levels were measured by ELISA
(R&D Systems).
Illumina Arrays and RT-PCR Analysis
Renal macrophages isolated byMiltenyi CD11bmag-
netic selection were 95 % purified populations [26]. Total
RNA was purified using RNeasy Kits (Qiagen) and the
RNA quality was checked with an Agilent Bioanalyzer
(Agilent Technologies). Microarray analysis was per-
formed using the Sentrix Mouse-6 v1.1 Illumina Whole
Genome Expression Beadchips according to the manufac-
turer’s protocol. Microarray data using background noise
subtracted and normalized data (BeadStudio v3.1 software)
was assessed as previously reported [27]. Data is shown as
the average signal intensity for TREM-1 and TREM-2
messenger RNA (mRNA) levels.
Renal cortex and medullas were isolated under a
dissecting microscope (Zeiss) and total cellular RNA was
prepared as previously described [25]. Quantitative poly-
merase chain reaction (Q-PCR) was performed to detect
TREM-1 mRNA expression in kidney tissue using the
TaqMan reverse transcription reagent (Applied
Biosystems). Primers were as follows: mouse TREM-1,
forward 5′-GAGCTTGAAGGATGAGGAAGGC-3′ and
reverse 5′-CAGAGTCTGTCACTTGAAGGTCAGTC-3′;
mouse β-actin, forward 5 ′-TGGAATCCTGTGG
C AT C C AT G A A A C - 3 ′ a n d r e v e r s e 5 ′ -
TAAAACGCAGCTCAGTAACAGTCCG-3. Expression
of TREM-1 was normalized to β-actin expression using
the standard ΔCT method.
Statistical Analysis
Data analysis was performed using the Mann-
Whitney U test or linear regression as described in the text
with either SigmaStat (SPSS, Chicago, IL) or GraphPad
Prism software (San Diego, CA).
RESULTS
Enhanced TREM-1 Expression in Anti-GBM-Induced
Nephritis in 129/SvJ Mice
We have previously shown that the 129/SvJ
strain is susceptible to a rapid onset glomerulonephri-
tis while C57BL/6 (B6) mice are relatively resistant
to anti-GBM nephritis [4, 23, 25, 28]. TREM-1 and
TREM-2 were undetectable in control kidneys by
immunohistochemistry (IHC) before induction of
anti-GBM disease. We examined the ratio of
TREM-1 to TREM-2 mRNA expression by macro-
phages in anti-GBM-diseased kidneys on day 7 by
Illumina arrays. An increased TREM-1/TREM-2 ratio
[TREM-1, 228.2 ± 18.6 (mean ± SD), TREM-2 931.2
± 184.2, (n = 3 each group)] was observed in 129/SvJ
kidneys as compared to control B6 kidneys [TREM-
1, 65.74 ± 9.06, TREM-2 4914 ± 566.9]. B6 macro-
phages displayed markedly increased TREM-2 ex-
pression. Of note, TREM-2 has been associated with
immunosuppressive myeloid cells. Thus, this finding
is consistent with the resistance of the B6 strain to
anti-GBM nephritis [15, 29, 30]. To confirm the
increased TREM-1 mRNA in 129/SvJ anti-GBM-
induced kidneys, we carried out real-time Q-PCR
(Fig. 1a). Elevations in TREM-1 mRNA levels were
found in the renal medulla of 129/SvJ mice, while
cortical TREM-1 levels were similar in both strains.
We next examined TREM-1 protein levels. Renal
eluates from anti-GBM-induced 129/SvJ mice
contained increased soluble TREM-1 protein levels
as compared to B6 controls (Fig. 1b). Although sol-
uble TREM-1 was elevated in the serum of 129/SvJ
compared to control B6 mice at later timepoints
(days 14 and 21), this was correlated with a slight
decrease in B6 serum soluble TREM-1 levels at days
14 and 21 in response to anti-GBM treatment
(Fig. 1c). There was no significant difference be-
tween 129/SvJ serum soluble TREM-1 levels on
day 0 compared to days 7, 14, and 21. (Fig. 1c).
Soluble TREM-1 levels normalized to urine creati-
nine were also significantly elevated in anti-GBM-
induced 129/SvJ urine on days 7, 14, and 21 as
compared to B6 controls (Fig. 1d). Moreover, soluble
TREM-1 levels were also elevated in the urine of
129/SvJ on day 21 compared to 129/SvJ on day 0
(P < 0.05). These studies confirmed that TREM-1
mRNA and protein were both elevated in anti-GBM
129/SvJ nephritis compared to the B6 controls. Thus,
increased renal TREM-1 levels correlated with dis-
ease severity.
TREM-1 Blockade Ameliorates Renal Injury
To determine whether TREM-1 played a pathogenic
role in anti-GBM-induced nephritis, we treated 129/SvJ
mice with an antagonistic TREM-1 peptide, LP17 [18,
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Fig. 1. Elevated TREM-1 mRNA and protein expression in anti-GBM-induced nephritis. Anti-GBM was induced and 7 days later, the kidneys were
examined for TREM-1mRNA and protein. a TREM-1mRNA levels were elevated in the renal medulla of 129/SvJ compared to B6mice. b TREM-1 protein
was detected by ELISA in renal eluates from 129/SvJ and control B6mice. c Soluble TREM-1 levels were reduced in the serum of control B6mice compared
to the 129/SvJ mice on days 14 and 21 as a result of an actual decrease in soluble TREM-1 levels in B6 mice over the course of disease. d Soluble TREM-1
was significantly elevated in the urine of 129/SvJ compared to control B6 mice. Soluble TREM-1 levels were also elevated in the urine of 129/SvJ on day 21
compared to 129/SvJ on day 0 (P < 0.05). Urine soluble TREM-1 levels were normalized to creatinine. TREM-1 blockade inhibits anti-GBM disease in 129/
SvJ mice. Anti-GBM-induced mice were randomly divided into three groups (n = 5 each) receiving (1) PBS, (2) control scrambled peptide, or (3) LP17
peptide. Mice received daily treatment with controls or LP17 peptide. e Serum creatinine levels were elevated on days 14–21 inmice receiving PBS or control
peptide, but only slightly elevated in LP17-treated mice. f Proteinuria was observed in control mice, but not in LP17-treated mice through day 21. Statistical
analysis was carried out by Mann-Whitney U tests to obtain the P values shown.
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31]. Renal function was monitored by assessing se-
rum creatinine levels and urine protein excretion
(Fig. 1e, f). Serum creatinine levels were elevated
on days 14 and 21 in vehicle and peptide control-
treated animals whereas minimal changes were ob-
served in LP17-treated mice (Fig. 1e). Proteinuria
was markedly increased in control animals on days
14 and 21, but not in samples from LP17-treated
mice (Fig. 1f). These studies suggest that anti-
GBM-induced renal impairment was significantly im-

























































































Fig. 2. The LP17 inhibitory peptide dampens anti-GBM nephritis in 129/SvJ mice. Anti-GBM-induced mice were randomly divided into three treatment
groups (n = 5) as in Fig. 1e, f. a An example of tissues from the three treatment groups is shown. Tissues were examined terminally for b glomerulonephritis
(GN) score, c percent crescent formation, and d tubulointerstitial nephritis (TI) score. e Examples of tissues prepared from the three treatment groups
examined for inflammatory cells (upper panel) or macrophages (lower panel). f Inflammatory cell infiltrate scores and g interstitial macrophage counts are
shown at day 21 after receiving anti-GBM serum. Statistical analysis was carried out by Mann-Whitney U tests to obtain the P values shown.
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Renal Pathology in LP17-Treated Mice
Consistent with reported findings, 129/SvJ kidneys
developed severe proliferative glomerulonephritis (GN)
including mesangial proliferation with increases in matri-
ces, focal necrosis, destruction of capillary lumens, and
crescent formation [12, 13, 25, 28]. Figure 2 shows that
renal disease, including GN score, percent crescent forma-
tion, and severity of tubulointerstitial (TI) disease, was
markedly reduced in LP17 treated mice, commensurate
with the dramatic reduction in the renal inflammatory
infiltrate and interstitial macrophages in LP17-treated
mice.
Correlation of TREM-1 Expression with Renal
Pathology
Finally, we correlated the TREM-1 expression in anti-
GBM-induced B6 and 129/SvJ kidneys with renal pathology
scores as shown in Fig. 3. TREM-1 eluted from the kidneys of






















































































Fig. 3. Correlation of TREM-1 expression with renal pathology. TREM-1 protein was detected in renal eluates from 129/SvJ and control B6 mice and
correlated with a TI score (r = 0.8, P = 0.0004), b GN score (r = 0.5, P = 0.02), and c serum creatinine (r = 0.4, P = 0.009) as described in Fig. 2. Urinary
soluble TREM-1 levels were also correlated with d TI score (r = 0.6, P = 0.006), e GN score (r = 0.5, P = 0.02), and f proteinuria (r = 0.5, P = 0.02) as
described in “MATERIALS AND METHODS.” Statistical analysis was carried out by linear regression to obtain the r and P values.
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anti-GBM-diseased mice with varying disease severity corre-
lated with tubulointerstitial disease (TI) score, glomerulone-
phritis (GN) score, and serum creatinine levels (Fig. 3a–c).
Similarly, there was a clear correlation between renal pathol-
ogy and urine soluble TREM-1 levels (Fig. 3d–f). Thus,
these studies demonstrate that elevated levels of
TREM-1 can be observed in anti-GBM-mediated ne-
phritis and correlate with the degree of renal disease.
DISCUSSION
Initial reports showed that monocytes, macrophages,
and neutrophils expressed the TREM-1 receptor and that it
was a potent costimulator of proinflammatory cytokines
[14–16]. More recent studies have found that TREM-1
mRNA and protein were elevated in inflammatory bowel
disease, experimental colitis, inflammatory arthritis, and
other noninfectious inflammatory diseases [14, 21, 22].
Moreover, TREM-1 activation in the absence of TLR
ligation or other stimuli induced myeloid cell cytokine
production including TNF, IL-6, IL-8, and MCP-1 in
in vitro cultures and disease models [14, 20, 21].
The current studies demonstrate that anti-GBM ne-
phritis is associated with increased expression of TREM-1
(CD354) protein and mRNA in renal tissue from the
129x1/SvJ mouse strain in contrast to the nephritis resistant
B6 strain. Urine levels of soluble TREM-1 but not serum
soluble TREM-1 increased significantly in samples from
the disease-susceptible 129x1/SvJ nephritic strain, indicat-
ing that the local production of TREM-1 in the inflamed
kidney might contribute to disease pathogenesis. Although
soluble TREM-1 and TREM-2 have been shown to attenu-
ate or restrain macrophage activation, our data suggest that
TREM-1 and TREM-2 expression levels are in part depen-
dent on genetic influences and that increased TREM-1
expression promotes the inflammatory state. Our immuno-
histochemistry studies in murine and human lupus renal
samples indicate that TREM-1 can be expressed by the
inflammatory infiltrate and renal epithelial cells in chronic
disease (manuscript in preparation). Thus, collectively, our
data suggest that genetics could influence the relative ex-
pression of TREM-1 by the inflamed target organ.
Our studies are the first to demonstrate the elevated
expression of renal TREM-1 in the nephritis-prone 129/
SvJ strain and indicate that TREM-1 plays a critical role in
the pathogenesis of inflammatory nephritis. Moreover,
these studies demonstrate, for the first time, that TREM-1
is amenable to therapeutic targeting for nephritis. TREM-1
blockade markedly reduced inflammation in immune-
mediated nephritis. These studies suggest that TREM-1
blockade might represent an effective novel strategy to be
incorporated into induction and possibly maintenance reg-
imens for patients with immune-mediated nephritis.
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